Assignee
PROTAGONIST THERAPEUTICS INC
US·30 granted patents·41 pending applications·493 citations·filing 2013–2025
Top patents by PatentIndex Score
71 records- 0198US11111272B2α4α7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·10 cites·14 claims
- 0298US10626146B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Apr 21, 2020·15 cites·22 claims
- 0398US9518091B2A4B7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Dec 13, 2016·34 cites·21 claims
- 0497US10941183B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Mar 9, 2021·13 cites·20 claims
- 0597US10301371B2Cyclic monomer and dimer peptides having integrin antagonist activityPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted May 28, 2019·19 cites·14 claims
- 0697US10196424B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·26 cites·22 claims
- 0797US10059744B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·22 cites·31 claims
- 0897US10035824B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 31, 2018·24 cites·26 claims
- 0997US10023614B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 17, 2018·23 cites·21 claims
- 1097US9809623B2α4β7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Nov 7, 2017·26 cites·14 claims
- 1197US9714270B2a4B7 integrin thioether peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·27 cites·22 claims
- 1297US9624268B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·40 cites·24 claims
- 1396US11472842B2Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·5 cites·11 claims
- 1496US10030061B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 24, 2018·29 cites·24 claims
- 1595US11807674B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·3 cites·4 claims
- 1695US11041000B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·13 cites·26 claims
- 1795US10729676B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·10 cites·18 claims
- 1895US10501515B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2019·18 cites·30 claims
- 1995US10442846B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·19 cites·19 claims
- 2095US9822157B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2014·Granted Nov 21, 2017·35 cites·9 claims
- 2195US9273093B2α4β7 peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2013·Granted Mar 1, 2016·31 cites·8 claims
- 2294US10278957B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·16 cites·19 claims
- 2393US10787490B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·18 cites·18 claims
- 2491US10407468B2Methods for synthesizing α4β7 peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·13 cites·24 claims
- 2588US11840581B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Dec 12, 2023·1 cites·17 claims
- 2688US2024199700A1Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2787US12269856B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
- 2886US11753443B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·3 cites·10 claims
- 2986US2024209026A1A4b7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3079US2025340608A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3178US12234300B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 3276US11884748B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·21 claims
- 3375US2022162261A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3472US2025327065A1Disulfide-rich peptide libraries and methods of use thereofPROTAGONIST THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3572US2020239523A1NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3671US2024132558A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3770US2024016895A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3870US2024066131A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3970US2024018189A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4069US12552836B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Feb 17, 2026·0 cites·21 claims
- 4168US2023295259A1Conjugated Hepcidin MimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4267US2025360187A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4364US2023382998A1METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4464US2025304624A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4564US2025361280A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4664US2018100004A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4762US2025170216A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4861US2018148477A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4961US2022041658A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5060US2024209053A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →